about
Mice lacking alpha-synuclein are resistant to mitochondrial toxinsTherapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.Promethazine protects against 3-nitropropionic acid-induced neurotoxicity.Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain.Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes.Prefrontal high-frequency stimulation prevents sub-conditioning procedure-provoked, but not acute stress-provoked, reemergence of extinguished fear.Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.Low-frequency stimulation of the ventral hippocampus facilitates extinction of contextual fear.Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.Magnesium Sulfate Prevents Neurochemical and Long-Term Behavioral Consequences of Neonatal Excitotoxic Lesions: Comparison Between Male and Female Mice.Prefrontal tetanic stimulation, following fear reconditioning, facilitates expression of previously acquired extinction.Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice.Molecular and electrophysiological changes in the prefrontal cortex-amygdala-dorsal periaqueductal grey pathway during persistent pain state and fear-conditioned analgesia.Large stem cell grafts could lead to erroneous interpretations of behavioral results?Why considering sexual differences is necessary when studying encephalopathy of prematurity through rodent models
P50
Q28511475-2B8DC5CD-EBB0-4C3C-B855-97678CDFE815Q34584417-4D9AAA06-422B-46E3-8BF5-39BFE46A49FDQ34706597-02A3ABF5-DDDB-4DF7-BDF7-A1C8C937E2FCQ36253348-74E5B192-AFD0-4120-92D2-52E6BE64A867Q38626004-9E7EF899-C30B-44C7-B66C-07F26F9CED4CQ40216832-47B51B62-4301-4C7E-986E-8408D78B9DEAQ44310635-79F30FA9-6688-4053-8F80-8D11014EE689Q44616097-F08AAFCD-E800-4F67-A58B-D067465FC243Q45207540-C2B17853-01EC-4318-A472-0136E5912146Q46079031-2CCA1363-6EE0-4D5C-949C-B0070EDD111DQ46644015-8614F1E4-5677-4F2D-A350-04FCFE7F5D30Q46673354-0386A4D9-B9EE-4345-99EF-2C071A50E093Q47251116-12BBE606-E0E9-4091-B460-3B2ADDF3CDECQ47944321-2FEBF5B6-B93D-4ABD-87B7-BA055B86114EQ48188310-971F761C-C555-4252-B129-EE446CE014D6Q49156450-A1D574C8-A5D1-407C-B1BF-11118A490858Q79751121-356F0BD6-28C3-4413-9225-C2C60B40FAB8Q92305005-580231E1-1D3E-409E-B0D4-9B0F4BB81452
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2451-8387
@en
name
Carine Cleren
@ast
Carine Cleren
@en
Carine Cleren
@es
Carine Cleren
@nl
type
label
Carine Cleren
@ast
Carine Cleren
@en
Carine Cleren
@es
Carine Cleren
@nl
prefLabel
Carine Cleren
@ast
Carine Cleren
@en
Carine Cleren
@es
Carine Cleren
@nl
P106
P1153
6506858311
P21
P31
P496
0000-0002-2451-8387